{"denoms":[{"counts":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"309"},{"groupId":"BG002","value":"312"},{"groupId":"BG003","value":"650"}],"units":"Participants"}],"groups":[{"description":"Temozolomide pre-randomization, radiation therapy pre-randomization. Note that for the purpose of this table, this arm only includes patients that did not continue to randomization.","id":"BG000","title":"Pre-Randomization TMZ+RT"},{"description":"Temozolomide post-randomization,Radiation therapy post-randomization, placebo","id":"BG001","title":"Randomized Arm 1: TMZ+RT + Placebo"},{"description":"Temozolomide post-randomization, radiation therapy post-randomization, bevacizumab","id":"BG002","title":"Randomized Arm 2: TMZ+RT + Bevacizumab"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"25","upperLimit":"75","value":"58"},{"groupId":"BG001","lowerLimit":"19","upperLimit":"82","value":"57"},{"groupId":"BG002","lowerLimit":"21","upperLimit":"82","value":"59"},{"groupId":"BG003","lowerLimit":"19","upperLimit":"82","value":"58"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"134"},{"groupId":"BG003","value":"260"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"194"},{"groupId":"BG002","value":"178"},{"groupId":"BG003","value":"390"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"All eligible patients. Note that the Pre-Randomization TMZ+RT arm only includes eligible patients that did not continue to randomization."}